Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zifang Guo

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
The New England Journal of Medicine|July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerJavier Cortes, Hope S Rugo, David W Cescon, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
The New England Journal of Medicine|July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerJavier Cortes, Hope S Rugo, David W Cescon, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
Pageof 4